U.S. markets close in 4 hours 50 minutes
  • S&P 500

    4,588.90
    -66.37 (-1.43%)
     
  • Dow 30

    34,614.61
    -521.33 (-1.48%)
     
  • Nasdaq

    15,559.98
    -222.86 (-1.41%)
     
  • Russell 2000

    2,207.37
    -34.60 (-1.54%)
     
  • Crude Oil

    67.24
    -2.71 (-3.87%)
     
  • Gold

    1,783.90
    -1.30 (-0.07%)
     
  • Silver

    22.88
    +0.03 (+0.12%)
     
  • EUR/USD

    1.1278
    -0.0015 (-0.14%)
     
  • 10-Yr Bond

    1.4820
    -0.0480 (-3.14%)
     
  • GBP/USD

    1.3229
    -0.0083 (-0.62%)
     
  • USD/JPY

    113.4860
    -0.1220 (-0.11%)
     
  • BTC-USD

    57,204.75
    +121.02 (+0.21%)
     
  • CMC Crypto 200

    1,465.24
    +22.47 (+1.56%)
     
  • FTSE 100

    7,072.07
    -37.88 (-0.53%)
     
  • Nikkei 225

    27,821.76
    -462.16 (-1.63%)
     

Are Atea Pharmaceuticals, Agenus, Novavax, and Ocular Therapeutix Bad News Buy?

·6 min read
Are Atea Pharmaceuticals, Agenus, Novavax, and Ocular Therapeutix Bad News Buy?
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Biotech stocks are in a slump. Despite numerous wins in the high-profile areas of COVID-19 and cancer therapy, the industry has failed to excite investors this year -- as seen in the 12% year-to-date fall in the the bellwether SPDR S&P Biotech ETF. Risk-tolerant growth investors appear to be favoring other vehicles over biotech in 2021, such as the red-hot cryptocurrency Shiba Inu (CRYPTO: SHIB), electric-vehicle giant Tesla (NASDAQ: TSLA), and emerging social media plays such as Digital World Acquisition (NASDAQ: DWAC) and Phunware (NASDAQ: PHUN).